Current and Future Cardiovascular PET Radiopharmaceuticals

Rami Al-Haddad; Uzair S Ismailani; Benjamin H Rotstein

doi:10.1016/j.cpet.2018.12.010

Current and Future Cardiovascular PET Radiopharmaceuticals

PET Clin. 2019 Apr;14(2):293-305. doi: 10.1016/j.cpet.2018.12.010. Epub 2019 Feb 1.

Authors

Rami Al-Haddad¹, Uzair S Ismailani¹, Benjamin H Rotstein²

Affiliations

¹ Department of Biochemistry, Microbiology and Immunology, University of Ottawa, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4E9, Canada.
² Department of Biochemistry, Microbiology and Immunology, University of Ottawa, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4E9, Canada. Electronic address: benjamin.rotstein@uottawa.ca.

PMID: 30826026
DOI: 10.1016/j.cpet.2018.12.010

Abstract

PET imaging is a continuously developing clinical tool for the imaging of different markers of cardiovascular diseases. In this article, some important PET tracers for several diseases affecting the heart and the vessels are highlighted; these include myocardial blood flow, atherosclerosis, fatty acid metabolism, and pathologies in the cardiac autonomic nervous system.

Keywords: Atherosclerosis; Cardiac autonomic nervous system; Cardiovascular diseases; Fatty acid metabolism; Myocardial blood flow; Positron emission tomography imaging; Radiotracers.

Publication types

Review

MeSH terms

Autonomic Nervous System Diseases / diagnostic imaging
Cardiovascular Diseases / diagnostic imaging*
Coronary Artery Disease / diagnostic imaging
Coronary Circulation / physiology
Fatty Acids / metabolism
Forecasting
Humans
Plaque, Atherosclerotic / diagnostic imaging
Positron-Emission Tomography / methods
Positron-Emission Tomography / trends*
Radioisotopes / chemistry
Radioisotopes / pharmacology
Radiopharmaceuticals / chemistry
Radiopharmaceuticals / pharmacology*

Substances

Fatty Acids
Radioisotopes
Radiopharmaceuticals